col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


55 Results       Page 1

 [1] 
Elsevier: Cytotherapy
  original article Date Title Authors   All Authors
1 [GO] 2024―Feb―15 Proteomics of serum-derived extracellular vesicles are associated with the severity and different clinical profiles of patients with COVID-19: An exploratory secondary analysis Adriana F. Paes Leme, Sami Yokoo, Ana Gabriela C. Normando, João Vitor S. Ormonde, Romenia Ramos Domingues, Fernanda F. Cruz, et al. (+7)
2 [GO] 2023―Oct―29 Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and/or lymphopenia (RELEASE NCT04578210) Cristina Ferreras, Clara Hernández-Blanco, Alejandro Martín-Quirós, Karima Al-Akioui-Sanz, Marta Mora-Rillo, Fátima Ibáñez, et al. (+30)
3 [GO] 2023―May―10 Mesenchymal Stem/Stromal Cells: HUMAN MESENCHYMAL STEM CELL THERAPY IN SEVERE COVID-19 PATIENTS: 2-YEAR FOLLOW-UP RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL T. Li, W. Yao, B. Zhang, H. Fang, M. Shi, Y. Zhang, et al. (+9)
4 [GO] 2023―May―10 Immunotherapy: OFF-THE-SHELF PARTIAL HLA MATCHING SARS-COV-2 ANTIGEN SPECIFIC T CELL THERAPY FOR SEVERE COVID-19 PATIENTS N. Kim, K. Im, J. Lee, D. Lee, D. Jekarl, E. Oh, S. Cho
5 [GO] 2023―May―10 Embryonic, Organ and Other Tissue Specific Stem Cells: BONE MARROW MESENCHYMAL STEM CELL DERIVED EXTRACELLULAR VESICLE INFUSION FOR SEVERE OR CRTIICAL COVID-19 RESPIRATORY FAILURE: A RANDOMIZED CLINICAL TRIAL A. Lightner, E. Schmidt, S. Sengupta, V. Sengupta, D. Park, T. Melson, et al. (+3)
6 [GO] 2023―May―10 Mesenchymal Stem/Stromal Cells: ON DEMAND MANUFACTURING STRATEGY TO DELIVER MULTIPLE DOSES OF FRESHLY CULTURED UMBILICAL CORD DERIVED MSCS IN THE CELLULAR IMMUNO-THERAPY FOR COVID-19 RELATED ARDS CLINICAL TRIAL S. Khan, S. English, S. Hodgins, M. Lalu, I. Watpool, J. Champagne, et al. (+7)
7 [GO] 2023―May―10 Mesenchymal Stem/Stromal Cells: SYSTEMATIC REVIEW AND META-ANALYSIS OF CELL THERAPY FOR COVID-19: GLOBAL CLINICAL TRIAL LANDSCAPE, PUBLISHED SAFETY/EFFICACY OUTCOMES, CELL PRODUCT MANUFACTURING AND CLINICAL DELIVERY N. Al-Arawe, P.S. Couto, I.S. Filgueiras, D.L. Fonseca, I. Hinterseher, R. Catar, et al. (+5)
8 [GO] 2023―May―10 Mesenchymal Stem/Stromal Cells: PRELIMINARY RESULTS FOR THE CELLULAR IMMUNO-THERAPY FOR COVID-19-RELATED ARDS MULTICENTRE CANADIAN RANDOMIZED CLINICAL TRIAL: CIRCA-19 PHASE 2 RCT D.J. Stewart, S. English, D. Fergusson, K. Soliman, M. Chassé, M. Lalu, et al. (+6)
9 [GO] 2023―May―10 Immunotherapy: EVALUATION OF MEMORY T CELLS AS ADOPTIVE THERAPY IN CORONAVIRUS PNEUMONIA AND/OR LYMPHOPENIA: A PHASE II CLINICAL TRIAL (RELEASE NCT04578210) C. Ferreras, C. Hernández, A. Martín-Quirós, K. Al-Akioui-Sanz, M. Mora-Rillo, F. Ibáñez, et al. (+16)
10 [GO] 2023―May―10 Immunotherapy: ADOPTIVE T CELL IMMUNOTHERAPY FOR SARS-COV-2 A. Henden, K. Lineburg, L. Le Texier, J. Raju, P. Crooks, E. Wright, et al. (+5)
11 [GO] 2023―May―10 Hematopoietic Stem/Progenitor Cells and Engineering: SARS-COV-2 INFECTS RED BLOOD CELL PROGENITORS AND DYSREGULATES HEMOGLOBIN AND IRON METABOLISM R. Kronstein-Wiedemann, M. Teichert, S. Traikov, M. Stadtmüller, H. Yosef, M. Georgi, et al. (+3)
12 [GO] 2023―May―10 Gene Editing/Gene Therapies: BIOREACTOR RECOMBINANT PRODUCTION OF SARS-COV-2 VIRUS ANTIGENS IN CHO CELL CLONES BY USING NEW UCOE LENTIVIRAL VECTOR SYSTEM O.F. Anakok, P. Kose, K.N. Bayindirli
13 [GO] 2023―Apr―17 A French single center experience on allogeneic stem cell transplant cryopreservation during SARS-CoV2 pandemic. C. Laroye, N. Thilly, M. Gauthier, A. Luc, V. Latger-Cannard, V. Eschwege, et al. (+6)
14 [GO] 2022―Dec―12 Donor selection for adoptive cell therapy with CD45RA- memory T cells for COVID-19 patients, and dexamethasone and interleukin-15 effect on the phenotype, proliferation and interferon gamma release Karima Al-Akioui-Sanz, Bárbara Pascual-Miguel, Mariana Díaz-Almirón, Carmen Mestre-Durán, Alfonso Navarro-Zapata, Laura Clares-Villa, et al. (+8)
15 [GO] 2022―Oct―24 SARS-COV-2 INFECTION AND REPLICATION KINETICS IN DIFFERENT HUMAN CELL TYPES: THE ROLE OF AUTOPHAGY, CELLULAR METABOLISM AND ACE2 EXPRESSION C.S. Bartolomeo, R.M.R. Lemes, R. Morais, G.C. Pereria, T.A. Nunes, A.J. Costa, et al. (+9)
16 [GO] 2022―Oct―13 Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat COVID-19: Is it too late? Aidan M. Kirkham, Adrian J.M. Bailey, Risa Shorr, Manoj M. Lalu, Dean A. Fergusson, David S. Allan
17 [GO] 2022―Aug―01 An ISCT MSC Committee Editorial on overcoming limitations in clinical trials of mesenchymal stromal cell therapy for COVID-19: Time for a global registry Daniel J. Weiss, Anthony Filiano, Jacques Galipeau, Maroun Khoury, Mauro Krampera, Manoj Lalu, et al. (+8)
18 [GO] 2022―Apr―25 Immunotherapy: TIMING OF DONOR SELECTION ON CD45RA-MEMORY T CELLS AS ADOPTIVE CELL THERAPY FOR COVID-19 K. Al-Akioui, M. Díaz-Almirón, J.L. Vicario, A. Balas, M. Moreno Hidalgo, B. Soria, et al. (+2)
19 [GO] 2022―Apr―25 Immunotherapy: TREATMENT WITH ALLOCETRA-OTS APOPTOTIC CELLS IN 21 SEVERELY/CRITICALLY ILL PATIENTS WITH COVID-19 D. Mevorach
20 [GO] 2022―Apr―25 Mesenchymal Stem/Stromal Cells: CONQUERING THE CYTOKINE STORM IN COVID-19 INDUCED ARDS USING PLACENTA-DERIVED DECIDUA STROMAL CELLS B. Sadeghi, E. Roshandel, A. Pirsalehi, S. Kazemi, G. Sankanian, M. Majidi, et al. (+7)
21 [GO] 2022―Apr―25 Exosomes/EVs: DESIGN OF A CLINICAL TRIAL TO TEST THE SAFETY OF AN AMNIOTIC FLUID-DERIVED EXTRACELLULAR VESICLE BIOLOGIC IN COVID-19 LONG HAULERS M.A. Bellio, C. Bennett, A. Khan, X. Xu, M. Mitrani
22 [GO] 2022―Apr―25 Process Development and Manufacturing: THE IMPACT OF THE COVID-19 PANDEMIC ON THE CELL AND GENE THERAPY SUPPLY CHAIN E. Hopewell, S. Leppke, O.J. Sturtevant
23 [GO] 2022―Apr―25 Mesenchymal Stem/Stromal Cells: MESENCURE: A PROFESSIONALIZED CELL THERAPY FOR ARDS REDUCED THE MORTALITY OF SEVERE COVID-19 PATIENTS BY 68% ACCORDING TO A RECENTLY CONCLUDED MULTI-CENTER, CONTROLLED PHASE II STUDY T. Bronshtein, D. Ben David, A. Novak, V. Kivity, T. Hayek, N. Rozen, et al. (+2)
24 [GO] 2022―Apr―25 Immunotherapy: SAFETY AND EFFICACY OF SARS-COV-2-SPECIFIC T CELLS AS ADOPTIVE IMMUNOTHERAPY FOR HIGH-RISK COVID-19 PATIENTS: A PHASE I/II, RANDOMIZED CLINICAL TRIAL A. Papadopoulou, G. Karavalakis, E. Papadopoulou, A. Xochelli, Z. Bousiou, A. Vogiatzoglou, et al. (+34)
25 [GO] 2022―Apr―25 Mesenchymal Stem/Stromal Cells: SAFETY OF CORD TISSUE DERIVED MESENCHYMAL STROMAL CELLS IN COVID-19 RELATED ACUTE RESPIRATORY DISTRESS SYNDROME B. Shaz, B. Kraft, J. Troy, E. Poehlein, L. Chen, L. Cheatham, et al. (+7)
26 [GO] 2022―Apr―25 Exosomes/EVs: CASE SERIES: THE COMBINATION OF RECOMMENDED TREATMENT PROTOCOLS WITH ADD-ON SECRETOME FROM UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS (UC-MSCS) THERAPY AS A MEDICAL STRATEGY FOR COVID-19 TREATMENT A. Adhiarta, C.R. Sartika, R. Haifa, N. Karina, N. Naura, D.K. Devi, V. Pertiwi
27 [GO] 2022―Apr―25 Regulatory Affairs, Quality Systems, Policy, and Ethics: AUTOLOGOUS CAR T CELL PRODUCT FROM COVID-19-POSITIVE PATIENT: MANUFACTURING AND REGULATORY CONSIDERATIONS D. Sikder, B. Senechal, X. Wang, M. Geyer, I. Riviere
28 [GO] 2022―Apr―25 Immunotherapy: OFF-THE-SHELF PARTIAL HLA MATCHING SARS-COV-2 ANTIGEN SPECIFIC T CELL THERAPY: A NEW POSSIBILITY FOR COVID- 19 TREATMENT N. Kim, J. Lee, E. Oh, D. Jekarl, D. Lee, K. Im, S. Cho
29 [GO] 2022―Apr―25 Immunotherapy: Late Breaking Abstract: GENERATION OF DONOR-DERIVED MULTI-VIRUS SPECIFIC T CELLS (VST) TARGETING CYTOMEGALOVIRUS (CMV), EPSTEIN-BARR VIRUS (EBV), ADENOVIRUS, BK VIRUS AND SARS-COV2 TO PREVENT VIRAL INFECTION IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AFTER BONE MARROW TRANSPLANT C. Motta, A. Abraham, M. Keller, C. Bollard
30 [GO] 2022―Apr―11 Mesenchymal Stromal Cell Therapy for Acute Respiratory Distress Syndrome due to COVID-19 Stacey-Ann Whittaker Brown, Camelia Iancu-Rubin, Adam Aboelela, Alex Abrahams, Elizabeth Burke, Tiffany Drummond, et al. (+7)
31 [GO] 2022―Jan―31 Mesenchymal stem/stromal cell-based therapies for COVID-19: First iteration of a living systematic review and meta-analysis Aidan M. Kirkham, Madeline Monaghan, Adrian J.M. Bailey, Risa Shorr, Manoj M. Lalu, Dean A. Fergusson, David S. Allan
32 [GO] 2021―Sep―14 iPSC-based disease modeling and prospective immune therapy for COVID-19 Koushik Chakrabarty, Rohit Shetty, Shubham Argulwar, Debashish Das, Arkasubhra Ghosh
33 [GO] 2021―Aug―17 Differentiation of immortalized human MLPC to alveolar type 2 (AT2)-like cells: ACE-2 expression and binding of SARS-CoV-2 spike and spike 1 proteins Daniel.P. Collins, Mark.J. Osborn, Clifford.J. Steer
34 [GO] 2021―May―31 Development of T cell immunity in a recipient of liver and hematopoietic stem cell transplant following COVID-19 infection. Mithil Soni, Edoardo Migliori, Amer Assal, Hei T Chan, Rodica Ciubotariu, Jian B. Pan, et al. (+4)
35 [GO] 2021―May―11 Pre-clinical development of T-cell immunotherapy for covid-19 C. Smith, A. Panikkar, J. Raju, S. Rehan, K. Lineburg, P. Crooks, et al. (+5)
36 [GO] 2021―May―11 Extracorporeal mesenchymal stromal cell therapy (SBI-101) in severe COVID-19 complicated by acute kidney injury J. Teixiera, M.G. Atta, L. Noureddine, S. Nguyen, B. O’Rourke, A. Tilles, et al. (+7)
37 [GO] 2021―May―11 Cryopreservation of allogeneic stem cell collections during covid-19 pandemic: Products characterization and engraftment outcome A. Keyzner, R. Jakubowski, Y. Sinitsyn, S. Tindle, S. Shpontak, U. Ozbek, et al. (+2)
38 [GO] 2021―May―11 Administration of amniotic fluid derived extracellular vesicle is associated with decreased crp in COVID-19 patients M. Mitrani, M.A. Bellio, G. Haskell, G.C. Shapiro
39 [GO] 2021―May―11 Breakthrough in treating severe coronavirus disease 2019 (COVID-19) patients in indonesia: the use of intravenous autologous activated platelet-rich plasma K. Karina, I. Rosliana, I. Rosadi, S. Sobariah, L.M. Christoffel, R. Novariani, et al. (+7)
40 [GO] 2021―May―11 Results of the cellular immuno-therapy for covid-19 related acute respiratory distress syndrome (circa-phase i trial S. English, D. Fergusson, M. Lalu, B. Thebaud, I. Watpool, J. Champagne, et al. (+6)
41 [GO] 2021―May―11 Manufacturing freshly cultured umbilical cord-derivedmesenchymal stromal cells (UC-MSCS) for a phase 1, multiple-dose clinical trial for COVID-19-induced acute respiratory distress syndrome (ARDS) S. Khan, S. English, S. Hodgins, M. Sobh, M. Lalu, I. Watpool, et al. (+6)
42 [GO] 2021―May―11 Mesencure-an enhanced cell therapy explicitly developed for treating acute respiratory distress in covid-19: from benchtop to bedside T. Bronshtein, D. Ben David, A. Novak, V. Kivity, S. Hamoud, T. Hayek, S. Meretzki
43 [GO] 2021―May―11 A phase I/II dose-escalation single center study to evaluate the safety of infusion of memory t cells as adoptive therapy in coronavirus pneumonia and /or lymphopenia (release) A. Perez-Martinez, C. Ferreras, M. Mora-Rillo, P. Guerra, B. Pascual-Miguel, C. Mestre-Durán, et al. (+16)
44 [GO] 2021―May―11 Cytokine optimization of SARS-CoV-2 specific T-cells for therapeutic use J.R. Durkee-Shock, C. Lazarski, M. Jensen-Wachspress, V. Kankate, H. Lang, P. Hanley, et al. (+2)
45 [GO] 2021―Apr―30 Mesenchymal Stromal Cell therapy for COVID-19: Which? When? And How Much? Pradnya Shahani, Indrani Datta
46 [GO] 2021―Apr―28 USE OF TOCILIZUMAB AND MESENCHYMAL STROMAL CELLS IN THE TREATMENT OF SEVERE COVID-19 - A CASE REPORT AC Senegaglia, CLK Rebelatto, CL Franck, JS Lima, DR Daga, P Shigunov, et al. (+12)
47 [GO] 2021―Apr―28 MESENCHYMAL STEM CELL TREATMENT FOR COVID-19: A 2021 UPDATE EM Garcez, F Saldanha-Araujo, AE Silva-Carvalho, JL Carvalho
48 [GO] 2021―Apr―28 ACE2 OVEREXPRESSION CHANGES THE SARS-COV-2 INFECTION PROFILE IN BEAS-2B CELLS CS Bartolomeo, TN Alves, RMR Lemes, GZ Ivanov, RLT Morais, AJ Costa, et al. (+12)
49 [GO] 2020―Dec―12 COVID-19 PANDEMIC AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER REAPPRAISAL Caterina Giovanna Valentini, Patrizia Chiusolo, Maria Bianchi, Elisabetta Metafuni, Nicoletta Orlando, Sabrina Giammarco, et al. (+3)
50 [GO] 2020―Nov―09 Stem cell therapy in COVID-19 - current evidence and future potential Rohit Shetty, Ponnalagu Murugeswari, Koushik Chakrabarty, Chaitra Jayadev, Himanshu Matalia, Arkasubhra Ghosh, Debashish Das
51 [GO] 2020―Sep―26 Temporary derogation of European environmental legislation for clinical trials of genetically modified organisms (GMOs) for COVID-19 C. Iglesias-Lopez
52 [GO] 2020―Aug―31 Antibodies at work in the time of SARS-CoV-2 Kuttuvan Valappil Sajna, Siya Kamat
53 [GO] 2020―May―16 ISEV and ISCT statement on EVs from MSCs and other cells: considerations for potential therapeutic agents to suppress COVID-19 Verena Börger, Daniel J. Weiss, Johnathon D. Anderson, Francesc E. Borràs, Benedetta Bussolati, David R.F. Carter, et al. (+25)
54 [GO] 2020―May―07 Emerging Trends in COVID-19 Treatment: Learning from Inflammatory Conditions Associated with Cellular Therapies Maria Cancio, Rachele Ciccocioppo, Patricia Rocco, Bruce Levine, Vincenzo Bronte, Catherine M. Bollard, et al. (+3)
55 [GO] 2020―Apr―17 Cell-Based Therapies for COVID-19: Proper Clinical Investigations are Essential Maroun Khoury, Patricia R.M. Rocco, Donald G Phinney, Mauro Krampera, Ivan Martin, Sowmya Viswanathan, et al. (+4)
 [1] 

55 Results       Page 1



[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.005 sec